Expert Perspectives News Today

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Key safety considerations for the use of fruquintinib are explored.